Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients.
The Impact of Cerianna PET/CT Results on the Therapeutic Decision in Patients with Known or Suspected Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions.
This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in ER-positive, HER2-negative metastatic breast cancer patients with progressive disease on first-line standard-of-care hormonal therapy. All patients will undergo a Cerianna PET/CT scan.
Inclusions/Exclusions: PD on 1st line AI. ECOG 0-2.